Genelux logo

Genelux

34 employees · est. 2001 · Westlake Village, United Sta...

VS
HiberCell logo

HiberCell

Developing Novel Therapeutics to Prevent Cancer Relapse and Metastasis

25 employees · est. 2019 · New York, United States

Genelux is the older company (2001 vs 2019).

Side-by-Side Comparison

Genelux HiberCell
Founded
2001 older 2019
Headquarters
Westlake Village, United States New York, United States
Employees
34 25
Industry
Biopharma, Biotechnology, Health Care Biotechnology, Health Care
Funding Stage
Post Ipo Equity Unknown
Total Funding
$98.98M $128.20M
Funding Rounds
5 2
Services
Development of oncolytic immunotherapy, Clinical trial management, Expanded access programs Development of therapeutic candidates (HC-7366, HC-5404), Clinical-stage research and trials, Exploiting stress-driven vulnerabilities in cancer cells
Target Customers
Cancer patients, Healthcare professionals, Clinical researchers Cancer patients, Healthcare providers, Biotech investors, Oncologists
Taxonomy
Oncolytic Immunotherapy, Solid Tumors, Cancer Treatment, Clinical-stage Biotech, Viral Therapy, Immunotherapies, Clinical Trials, Cancer Research, Cancer Therapy, Personalized Medicine Oncology, Therapeutics, Cancer, Metastasis, Clinical Stage, Adaptive Stress Pathways, Anti-tumor Immunity, Product Candidates, Phase 1a Clinical Trials, Cancer Relapse Prevention, New York, Treatment Resistance, Stress Response Kinases, Innate Immune Response
Website
genelux.com hibercell.com
Genelux logo

About Genelux

Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology firm founded in 2001 and based in the United States. The company operates at the forefront of the Biopharma, Biotechnology, and Health Care industries, focusing on oncolytic immunotherapy to improve patient outcomes in cases o...

HiberCell logo

About HiberCell

HiberCell, founded in 2019 and headquartered in the United States, is a pioneering force in the Biotechnology and Health Care industries. With a focus on developing novel therapeutics, the company aims to prevent cancer relapse and metastasis. Its slogan, "Developing Novel Therapeutics to Prevent Ca...

Be first to know when either one moves

Funding rounds, hiring surges, leadership changes and stack switches at Genelux and HiberCell — tracked continuously, sent the day they land.

Watch both — free

Funding, hiring, leadership and stack changes at Genelux and HiberCell — by email.

Frequently Asked Questions

Genelux. HiberCell — Developing Novel Therapeutics to Prevent Cancer Relapse and Metastasis. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Genelux has raised $98.98M while HiberCell has raised $128.20M.
Genelux and HiberCell operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Genelux with someone else

Start typing a company name or domain.

One analytics cookie (Google Analytics). Cookie Policy